MediWound announces successful GMP audit by the Israeli Ministry of Health

MediWound Ltd. announces the successful completion of a Good Manufacturing Practices (GMP) audit of its facility in Yavne, Israel by the Israeli Ministry of Health (IMOH). MediWound is fully integrated, biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management.

The IMOH conducted the audit as a part of routine inspection of the Company’s manufacturing facility for its proteolytic enzyme therapeutics. And the audit concluded that MediWound’s manufacturing facility is compliant to the requirements of cGMP for the manufacture of sterile and biological medicinal products. This compliance status is valid for three years from the time of the audit. As the IMOH is also a member of the Pharmaceutical Inspection Convention and Pharmaceutical Inspection Co-operation Scheme, this audit is also issued under the provisions of the Conformity Assessment and Acceptance of Industrial Products Agreement between the European Union and Israel.

The Company’s spokesperson said that as a fully integrated company, manufacturing is a core competency of MediWound and is critical for our commercial success. We take great pride in maintaining the highest quality standards and this positive audit underscores the viability, quality and high standards MediWound upholds in the manufacture of our proteolytic enzyme therapeutics for commercial use and for products under development in compliance with rigorous international standards.